CorMedix (CRMD) Stock: Buy, Sell, or Hold?
CRMD - CorMedix Inc.
$7.85
-0.25 (-3.09%)
âŧ
5d:
+8.13%
30d:
+1.03%
90d:
+3.29%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 11, 2026
16d
Get Alerted When CRMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CRMD is fairly priced but lacks strong directional signals. At 39.2% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CRMD is fairly priced but lacks strong directional signals. At 39.2% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CRMD is currently trading at $7.85, which is considered fair relative to its 30-day fair value range of $7.34 to $7.81. From a valuation perspective, the stock is trading at a premium (Forward PE: 138.4) compared to its historical average (51.4). At these levels, the market is pricing in 39.2% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CRMD is in a downtrend. Immediate support is located at $7.16, while resistance sits at $8.12. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: CRMD scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.33 (+95.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRMD is in a downtrend. Immediate support is located at $7.16, while resistance sits at $8.12. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: CRMD scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.33 (+95.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.34 -
$7.81
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
40.5%
Protect Your Profits
Holding CRMD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 95.3% below Wall St target ($15.33)
- BEARISH: Market expects 39.2% growth - appears too optimistic based on history
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.34 -
$7.81
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$7.16
Resistance Level
$8.12
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
138.45
Wall Street Target
$15.33
(+95.3%)
Revenue Growth (YoY)
156.5%
Earnings Growth (YoY)
6.7%
Profit Margin
40.5%
Valuation Premium vs History
+39.2% premium
PE vs Historical
138.5 vs 51.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+39.2%
(market-implied from PE analysis)
1-Year Target
$10.93
(+39%)
2-Year Target
$15.21
(+94%)
3-Year Target
$21.17
(+170%)
3-Yr Target (if PE normalizes)
(PE: 138â51)
PE COMPRESSION
$7.86
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 138.4, Growth: -88.5%)
$5.72
(+-27%)
Base:
(SPY PE: 19.9, Growth: -88.5%)
$0.82
(-90%)
Bear:
(PE: 16.9, Growth: -88.5%)
$0.70
(-91%)
đ
Valuation based on Current Earnings
Trailing PE: 3.80 | Current EPS (TTM): $2.13
Bull Case
$4.45
(-43%)
Analyst growth -50.0%, PE expands to 4.2
Base Case
$4.05
(-48%)
Market implied -50.0%, PE stable at 3.8
Bear Case
$5.51
(-30%)
Severe decline -20.0%, PE contracts to 3.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 24, 2026 8:41 PM ET
Data refreshes hourly during market hours. Next update: 9:41 PM
Data refreshes hourly during market hours. Next update: 9:41 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 72 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 69 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 56 HOLD |
Advanced CRMD Option Strategies
Professional options setups generated by AI based on today's CRMD price and gamma walls.
